




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 229/36, 271/14, 271/12, 311/06, A61K 31/195, 31/215	A1	(11) International Publication Number: WO 98/09938 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/EP97/04271 (22) International Filing Date: 31 July 1997 (31.07.97) (30) Priority Data: 9618349.6 3 September 1996 (03.09.96) GB (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): VARASI, Mario [IT/IT]; Via Giambellino, 80, I-20146 Milano (IT). GIORDANI, Antonio [IT/IT]; Via Ceva, 18, I-27100 Pavia (IT). CINI, Massimo [IT/IT]; Via Carnia, 15, I-20020 Lainate (IT). SPECIALE, Carmela [IT/IT]; Via Giovanni XXIII, 21, I- 20014 Nerviano (IT). BIANCHETTI, Alberto [IT/IT]; Via Corridoni, 11, I-20100 Milano (IT).		(81) Designated States: AL, AU, BG, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: N-SUBSTITUTED-2-AMINO-4-PHENYL-4-OXO-BUTANOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITORY ACTIVITY		
(57) Abstract <p>N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of formula (I), wherein each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SO₂R₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or benzyl; R is hydroxy, -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in which each of R₃ is as defined above; W is -COOR₄, -COR₄ or -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl; -CONHR₅ or -CSNHR₅ in which R₅ is as defined above; trichloroacetyl; or trifluoroacetyl; or a pharmaceutically acceptable salts thereof, for use as a medicament, in particular as Kynurenine 3-hydroxylase inhibitor is disclosed.</p> <div style="text-align: center;">  </div> <div style="text-align: right;">(I)</div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid
derivatives with kynurenine-3-hydroxylase inhibitory
5 activity.

The present invention refers to the use in the prevention and/or treatment of neurodegenerative diseases, such as, for example, Huntington's chorea,
10 Alzheimer's disease, dementia caused by acquired immunodeficiency syndrome (AIDS), infarctual dementia, cerebral ischemia, cerebral hypoxia, Parkinson's disease, epilepsy, head and spinal cord injury, amyotrophic lateral sclerosis, glaucoma/retinopathy, infections and
15 inflammations of the brain, of N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid derivatives which act as inhibitors of kynurenine-3-hydroxylase (KYN-3-OHase), the enzyme which forms part of the metabolic pathway of kynurenine.

20 A second object of this invention is directed to a restricted class of the above N-substituted-2-amino-4-oxo-4-phenyl-butanoic acid derivatives as novel compounds, either as single enantiomers or as mixture of enantiomers, to their pharmaceutically acceptable salts,
25 to a process for their preparation, and to pharmaceutical compositions containing them.

In the central nervous system (CNS) the metabolism of tryptophan is well known to result largely in the production of indolamines such as the neurotransmitter
30 serotonin, while in the periphery most of non-peptide tryptophan utilisation is along the kynurenine pathway, ultimately leading to the formation of nicotinamide


adenine dinucleotide (NAD) (Fig.1). The legend to Fig. 1 is to be found on the last page of the experimental part. In the last decade several lines of evidence have demonstrated that two intermediates of the kynurenine metabolism, quinolinic acid (QUIN) and kynurenic acid (KYNA), when injected in the CNS, act as a neurotoxin and as a neuroprotectant, respectively. Consequently, the demonstration that these two metabolites of the kynurenine pathway (unable to cross the blood brain barrier), are normal constituents of the mammalian brain, has suggested the existence of this pathway within the CNS and proposed the involvement of QUIN and KYNA in brain physiology and pathology (Stone T.W., Pharmacol. Rew., (1993), 310-379). Both QUIN and KYNA are able to interact with the ionotropic excitatory amino acid receptors. In particular, QUIN is a highly selective agonist at N-methyl-D-aspartate (NMDA) receptor (Stone T.W., Eur. J. Pharmacol., 72, (1981) 411-412), whereas KYNA is a broad spectrum antagonist of the ionotropic excitatory aminoacid receptors, preferentially acting at the glycine co-agonist site of the NMDA receptor (J. Neurochem., 52, (1989) 1319-1328). In vitro studies have demonstrated that the exposure of neuronal cell cultures to relatively low QUIN concentrations are neurotoxic either when applied over a prolonged period of time or in combination with glutamate (Schurr A., Brain Res., 568, (1991) 199-204). In vivo QUIN has been shown to produce convulsions and axon sparing lesions that mimic the nerve cell loss described in human neurodegenerative disorders (Schwarcz R., Science, 219, (1983) 316-318). Moreover an increase in QUIN production has been demonstrated in post-ischemic gerbil brain (Saito K., J. Neurochem., 60,

(1993) 180-192), following spinal cord trauma in rats (Stokes B.T., Brain Res., 633, (1994) 348-352) and in guinea pig (Blight A.R., Brain Res., 632, (1993) 314-316), and, finally, in a model of experimental allergic encephalomyelitis (Flagan E.M., J.Neurochem., 64, (1995) 1192-1196). On the other hand, KYNA has shown anticonvulsant and neuroprotective properties in several animal models (Stone T.W. Pharmacol.Rev.45,(1993) 309-379), and, additionally, the experimentally-evoked rise of KYNA concentrations is capable to elicit neuroprotection and seizures reduction (Nozaki K., J. Cereb. Blood Flow Metab., (1992), 12, 400-407; Russi P., J. Neurochem., 59, (1992) 2076). Notably, KYNA when co-injected with QUIN is able to prevent the excitotoxic neuronal damage evoked by the neurotoxin (Foster A.C., Neurosci. Lett., 48, (1984) 273-278). These data taken together suggest that KYNA may act as the brain's own defence against detrimental events, such as excitotoxicity and seizures, leading to pathological situations (Schwarcz R., Neurotoxin and neurodegenerative disease, Ann. N.Y.Sci., 140, vol. 648, 1992). It follows that pharmacological interventions aimed at increasing KYNA formation and/or blocking QUIN synthesis can be useful in the treatment of excitotoxic brain diseases. In the Kynurenine pathway (see Fig.1), KYN-3-OHase is the first enzyme involved in the formation of QUIN from kynurenine. Pharmacological agents acting as inhibitors of this enzyme able to block the metabolism toward QUIN and, at the same time, to increase KYNA formation, can be useful as neuroprotective agents in the prevention and/or treatment of all the neurodegenerative pathologies involving quinolinic acid or excessive activation of

neurotransmission mediated by excitatory amino acid (EAA) receptors.

There is therefore a need to find pharmacological substances which can be useful as neuroprotective agents by means of their activity as inhibitors of the enzyme KYN-3-OHase. The present invention fulfills such a need.

Accordingly, the present invention provides a N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of formula (I)



wherein

each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SOR₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or benzyl;

R is hydroxy; -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in which each of R₃ is as defined above;

W is -COOR₄, -COR₄ or -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl; -CONHR₅ or -CSNHR₅ in which R₅ is as defined above; trichloroacetyl; or trifluoroacetyl; and the pharmaceutically acceptable

salts thereof, for use as a medicament, in particular as Kynurenine 3-hydroxylase inhibitors.

A preferred class of compounds of formula (I) are those wherein

5 each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SOR₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl,
10 C₂-C₄ alkynyl, optionally substituted phenyl or benzyl;

R is hydroxy;

W is -COOR₄, -COR₄ or -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl, trichloroacetyl or
15 trifluoroacetyl; and the pharmaceutically acceptable salts thereof.

Examples of specific compounds of formula (I) are the following:

N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)
20 butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chlorophenyl)-
butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluorophenyl)-
butanoic acid;
25 N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-
butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-difluorophenyl)-
butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chloro-4'-
30 methoxyphenyl)-butanoic acid;
N-acetyl-2-amino-4-oxo-4-(3',4'-dichloro phenyl)butanoic
acid;


- N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluoro-4'-methoxyphenyl)-butanoic acid;
N-benzoyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
5 N-methoxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
N-benzyloxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid; either as single enantiomers or as mixture of enantiomers and the
10 pharmaceutically acceptable salts thereof.

The following compounds of formula (I) either as single enantiomers or as a mixture thereof, and the pharmaceutically acceptable salts thereof are novel compounds and are a further object of this invention:

- 15 N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chlorophenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluorophenyl)-
20 butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chloro-4'-methoxyphenyl)-butanoic acid;
N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluoro-4'-methoxyphenyl)-butanoic acid;
25 N-benzoyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
N-methoxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid; and
N-benzyloxycarbonyl-2-amino-4-oxo-4-(3',4'-
30 dichlorophenyl)-butanoic acid.

The present invention also refers to a selected class of compounds of formula (I) which are novel compounds.

Accordingly, a further object of the invention, is a compound of the following formula (Ia)



wherein

each of the groups X and Y is, independently,
 10 hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SO₂R₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or
 15 benzyl;

R is hydroxy; -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in which each of R₃ is as defined above;

W is -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally
 20 substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl; -CONHR₅ or -CSNHR₅ in which R₅ is as defined above; and the pharmaceutically acceptable salts thereof.

Preferred compounds of formula (Ia) are those wherein
 25 W is SO₂R₄ in which R₄ is C₁-C₄ alkyl and X and Y, which may be the same or different are hydrogen or halogen.

A preferred example of a compound of formula (Ia) is N-methylsulphonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid, either as single enantiomer

or as a mixture thereof, and the pharmaceutically acceptable salts thereof.

With reference to formula (I) and (Ia), the preferred meanings of the various substituents are as follows.

5 The alkyl and alkoxy groups may be branched or straight groups.

Representative examples of a C₁-C₆ alkyl group include methyl, ethyl, *n*- and *iso*-propyl, *n*-, *iso*-, *sec*- and *tert*-butyl.

10 Representative examples of a C₁-C₆ alkoxy group include methoxy and ethoxy.

Representative examples of a C₁-C₆ alkylthio group include methylthio, ethylthio and isopropylthio.

15 Representative examples of a C₂-C₄ alkenyl group include ethenyl, 1-propenyl and 2-propenyl.

Representative examples of a C₂-C₄ alkynyl group include ethynyl, 1-propynyl and 2-propynyl.

20 A substituted phenyl or benzyl ring is, preferably, a methoxy, a halogen or a nitro substituted phenyl or benzyl ring.

Halogen includes fluoro, bromo, chloro and iodo; in particular fluoro or chloro.

25 The compounds of formula (I) or (Ia) have an asymmetric carbon atom and, for this reason, they can exist either as a mixture of optical isomers (enantiomeric mixture) or as single optical isomer (enantiomer). The present invention includes within its scope all the possible isomers and their mixtures and both the metabolites and the pharmaceutically acceptable
30 bioprecursors (otherwise known as pro-drugs) of the compounds of formula (I) or (Ia).


The pharmaceutically acceptable salts of the compounds of formula (I) or (Ia) include the salts of inorganic bases, for example hydroxides of alkali metals, e.g. sodium or potassium, or alkaline-earth metals, e.g. calcium or magnesium, and the salts of organic bases such as, for example, aliphatic amines, e.g., methyl amine, ethyl amine or diethyl amine, or heterocyclic amines, e.g. piperidine.

The novel and known compounds of formula (I), the novel chemical entities of formula (I) and the selected class of formula (Ia) included, and the pharmaceutically acceptable salts thereof are therein defined as "the compounds of the invention" and as "the active compounds of the invention".

Object of the invention is also to provide the use of a compound of the invention in the manufacture of a medicament for use as kynurenine-3-hydroxylase inhibitor.

The invention also provides a method of inhibiting kynurenine-3-hydroxylase enzyme in a mammal, including humans, in need of such inhibition, comprising administering to the mammal a kynurenine-3-hydroxylase enzyme-inhibiting effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

Most of compounds of the present invention, either as racemic mixture or as pure enantiomers may be prepared in a single step process, following the same procedure described from page 19, line 9, to page 22, of the International Patent Application PCT/WO 95/03271, which is reported in the following Scheme 1.

Scheme 1

5 In the above Scheme 1:

X and Y are, each independently, hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy or C_1 - C_6 alkylthio;

R is hydroxy; and

W is $-COOR_4$ or COR_4 in which R_4 is C_1 - C_6 alkyl, an
 10 optionally substituted phenyl or benzyl, or trifluoroacetyl.

A compound of formula (I), obtained following the above procedure, can be converted into another compound of formula (I) in which R is other than hydroxy,
 15 according to known methods.

The reaction of a compound of formula (II) with a compound of formula (III), as described in Scheme 1, can be carried out according to known methods (e.g. J.E. Norlander, J.Org. Chem., 50, 3619-22, 1985; D.G. Melillo,
 20 J.Org. Chem., 52, 5143-50, 1987).

For example, the reaction can be performed in the presence of a suitable Lewis acid catalyst, in an inert solvent such as, e.g. dichloromethane or 1,2-dichloroethane, or in an appropriate aromatic hydrocarbon
 25 such as, e.g. chlorobenzene, nitrobenzene or in an excess of compound of formula (II) itself; at a temperature


ranging from about -10°C to about 100°C, optionally in the presence of a suitable co-solvent, e.g. nitromethane. A suitable Lewis acid may be, for example, anhydrous aluminium trichloride, anhydrous tin dichloride, titanium tetrachloride or anhydrous zinc dichloride, typically anhydrous aluminium trichloride.

The compounds of formula (II) are known compounds.

The compounds of formula (III) are known compounds or can be prepared by known procedures from known compounds.

Alternatively, a compound of formula (I) or (Ia) can be obtained according to the following Scheme 2.

Scheme 2



In the above Scheme 2:

each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SOR₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or benzyl;

R is hydroxy; -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in which each of R₃ is as defined above;

Q is hydroxy; halogen; R₄COO- in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an

optionally substituted phenyl or benzyl; trichloroacetoxy; or trifluoroacetoxy; and

W is $-\text{COOR}_4$, $-\text{COR}_4$ or $-\text{SO}_2\text{R}_4$ in which R_4 is as defined above; $-\text{CONHR}_5$ or $-\text{CSNHR}_5$ in which R_5 is as defined above;
5 trichloroacetyl; or trifluoroacetyl.

The compounds of formula (IV) are either known compounds or can be prepared according to known methods from known compounds.

The compounds of formula (V) are commercially available
10 compounds or prepared from commercially available compounds using known methods.

The reaction of a compound of formula (IV) with a compound of formula (V), as described in Scheme 2, can be carried out according to methods well known in the art;
15 for example, those usually employed in the synthesis of N-protected aminoacid or of peptides. More in detail, a compound of formula (IV) may be reacted with an acid chloride of formula (V) in the presence of an organic or inorganic base, in a customary organic solvent such as,
20 for example, dichloromethane, tetrahydrofuran or an excess of the base itself (e.g. pyridine).

Other examples of suitable organic bases are triethylamine and N-methylmorpholine, examples of inorganic bases are sodium or potassium carbonate or
25 bicarbonate, in this last case the reaction may be carried out in a two phases system using, if desired, a phase transfer catalyst. The reaction temperature may range from room temperature to about -40°C .

Alternatively, the reaction may be carried out in water
30 using classical Schotten-Bauman conditions at temperature ranging from about 0°C to room temperature

A compound of formula (IV) may be reacted with an acid anhydride of formula (V).

A compound of formula (IV) may be reacted with an acid of formula (V) via an intermediate derivative thereof, which
5 can be isolated or not. An intermediate derivative may be an active ester, e.g. a nitro-phenyl ester or an N-hydroxysuccinimide ester, a mixed anhydride, e.g. an ethoxycarbonyl or iso-butyloxycarbonyl anhydride, or a reactive intermediate obtained "in situ" by reaction of
10 the acid with dicyclohexylcarbodiimide or carbonyl diimidazole.

For example, an acid of formula (V) and a compound of formula (IV) wherein R is $-OR_5$, $-N(R_3)_2$ or $-N(R_3)OR_3$ in which R_5 and R_3 are as defined above, may be reacted with
15 dicyclohexylcarbodiimide, if desired, in the presence of a suitable catalyst (e.g. dimethylaminopyridine or N-hydroxybenzotriazole), in an organic solvent (e.g. dichloromethane), at a temperature ranging from about 0°C to room temperature.

20 A compound of formula (I) or (Ia) which contains a free carboxy group, namely a compound of formula (I) or (Ia) in which R is hydroxy, can be converted into another compound of formula (I) or (Ia) in which R is other than hydroxy. This conversion may be carried out according to
25 well known methods. For example, a compound of formula (I) or (Ia) wherein R is hydroxy, can be converted into another compound of formula (I) or (Ia) wherein R is $-OR_5$ in which R_5 is as defined above, by usual esterification methods, for example, following the procedure described
30 in: E. Haslam, Tetrahedron, 36, 2409-2433 (1980). Preferably, such an esterification reaction can be carried out via a reactive derivative intermediate of the

carboxylic acid, which may be isolated or not, by reaction with the appropriate alcohol of formula R_5OH in which R_5 is as defined above. The reaction can be carried out in a customary solvent, e.g. dichloromethane, tetrahydrofuran, toluene, or in the presence of an excess of the alcohol itself of formula R_5OH , at a temperature which may range from about $-20^\circ C$ to about $50^\circ C$. Intermediate reactive derivatives of the carboxylic acid may be, for example, acid halides, e.g. chloride, mixed anhydrides, e.g. etoxycarbonyl or tert-butyloxy anhydride, or a suitable reactive intermediate obtained "in situ", for example, by reaction with a diimide, e.g. dicyclohexylcarbodiimide or carbonyl diimidazole.

The esterification reaction may be also carried out by treatment of a compound of formula (I) or (Ia) in which R is hydroxy, with a suitable alkylating agent of formula R_5-L in which R_5 is as defined above and L is an appropriate leaving group such as, e.g. a halogen atom, preferably iodine, or a sulfate ester, in the presence of an inorganic base, e.g. potassium carbonate or bicarbonate, or in the presence of an organic base, e.g. 1,8-diazabicyclo[5.4.0]-undec-7-ene(1,5-5) (DBU), in a suitable solvent, e.g. dimethylformamide, at a reaction temperature that may range from about $0^\circ C$ to about $60^\circ C$.

Furthermore, a compound of formula (I) or (Ia) wherein R is hydroxy, can be converted into a corresponding compound of formula (I) or (Ia) wherein R is $-N(R_3)_2$ or $-N(R_3)OR_3$ wherein R_3 is, independently, hydrogen, benzyl or C_1-C_6 alkyl, according to known methods; preferably, via an intermediate reactive derivative thereof, which can be isolated or not. Intermediate derivatives may be active esters, e.g., NO_2-

phenyl esters or N-hydroxysuccinimide esters, acid halides preferably chlorides, mixed anhydrides, e.g. ethoxycarbonyl or iso-butyloxycarbonyl anhydrides, or reactive intermediates obtained "in situ" by reaction of
5 the acid with dicyclohexylcarbodiimide or carbonyl diimidazole.

For example, a reactive intermediate as defined above, which can be obtained following conventional ways, is reacted with ammonia or an appropriate amine $\text{HN}(\text{R}_6)_2$
10 or an appropriate hydroxylamine or protected hydroxylamine of formula $\text{HNO}-\text{R}_7$, wherein R_7 is a suitable C_1-C_6 alkyl or benzyl substituent or protecting group; in this last case, R_7 is preferably a benzyl or trialkylsilyl group. The reaction solvent may be a customary
15 solvent, such as e.g., dichloromethane, tetrahydrofuran, dioxane or an excess of the amine itself, and the reaction temperature may range from about -20°C to about 50°C .

The optional salification of a compound of formula
20 (I) or (Ia) as well as the conversion of a salt into the corresponding free compound and the separation of a mixture of isomers into the single isomer, may be carried out by usual methods.

For example, the separation of a mixture of
25 regioisomers obtained as described in Scheme 1, into the single isomer may be carried out by conventional methods. Particularly, the separation of regioisomers may be carried out by fractional crystallization from a suitable solvent or by chromatography, either flash column
30 chromatography or high pressure liquid chromatography.

As previously described, the compounds of formula (I) or (Ia) can exist as enantiomers; the separation of

the racemic compounds of formula (I) or (Ia) into the corresponding pure enantiomers can be carried out according to techniques and procedures well known in the art; for example, either high pressure liquid
5 chromatography on a chiral stationary phase, or resolution via diastereoisomeric salt formation of a compound of formula (I) or (Ia) wherein R is hydroxy, with a suitable optically active organic base, e.g., phenylethylamine, ephedrine or brucine, and subsequent
10 separation of the pure diastereoisomeric salt by selective recrystallisation.

It is understood that the preparation of the compounds of formula (I), according to the methods described above, comprises the preparation of the
15 compounds of formula (Ia) which represent a selected class of compounds of formula (I).

PHARMACOLOGY

As already said, the compounds of the invention are active as kynurenine-3-hydroxylase inhibitors.

20 The efficacy of the compounds of the invention in the inhibition of the enzyme kynurenine-3-hydroxylase has been evaluated in rat brain homogenate, determining the conversion of L-kynurenine to L-3-hydroxy-kynurenine according to the method described below.

25

(A) Kynurenine-3-hydroxylase assay in the rat brain

Brain was homogenized in ice-cold 0.32 M sucrose and centrifuged at 12000 x g for 30 min at 4°C. The pellet was washed three times with 0.32 M sucrose by
30 centrifugation and suspended in 0.14 M KCl in 20 mM K-phosphate buffer at pH 7 (1 g tissue in 2 ml buffer).

The reaction mixture contained: 75 μ l of suspended homogenate; 100 μ l of substrate solution containing 50 mM K-phosphate buffer pH 7.5, 2 mM $MgCl_2$, 0.4 mM NADPH and 50 μ M L-kynurenine (final concentration): 25 μ l of
5 different concentrations of inhibitor solutions). The reaction was stopped by addition of 200 μ l of 1 M $HClO_4$ after 60 min incubation. L-3-hydroxykynurenine formed was quantified by HPLC with coulometric detection at a working voltage of +0.2 V. The column was a 10 cm C_{18}
10 reversed phase (3 μ m. The mobile phase consisted of 950 ml distilled water, 20 ml acetonitrile, 9 ml triethylamine, 5.9 ml phosphoric acid, 100 mg sodium EDTA and 1.5 g heptanesulfonic acid. The flow rate was 1 ml/min.

15 As an example, the compounds of the present invention:

(R,S)-N-trifluoroacetyl-2-amino-4-(3',4'-dichlorophenyl)-4-oxo-butanoic acid (FCE 29256*);

(S)-N-trifluoroacetyl-2-amino-4-(3',4'-dichlorophenyl)-4-oxo-butanoic acid (FCE 29435*); and
20 (R,S)-N-trifluoroacetyl-2-amino-4-(3',4'-difluorophenyl)-4-oxo-butanoic acid (FCE 29434*);

(* means "Internal Code")

have been tested according to the Method (A) described
25 above.

The obtained results, are reported in the following Table 1.

Table 1

Enzyme Inhibition:	(Rat brain)
Compound	IC 50 (μ M)
FCE 29256	0.14
FCE 29435	0.24
FCE 29434	0.27

The tested compounds, which are representative of the
5 compounds of the invention, were found to be
significantly active in inhibiting the enzyme kynurenine-
3-hydroxylase.

The compounds of the invention are therefore useful
in preventing or treating a disease state in mammals,
10 including humans, wherein inhibition of kynurenine-3-
hydroxylase is needed.

In particular, the compounds of the invention can be
useful as neuroprotective agents in the prevention and/or
treatment of a neurodegenerative disease which comprises:
15 Huntington's chorea, Alzheimer's disease, dementia caused
by acquired immunodeficiency syndrome (AIDS), infarctual
dementia, cerebral ischemia, cerebral hypoxia,
Parkinson's disease, epilepsy, head and spinal cord
injury, amyotrophic lateral sclerosis,
20 glaucoma/retinopathy, infections and inflammation of the
brain.

The compounds of the present invention can be
administered in a variety of dosage forms, e.g. orally,
in the form of tablets, capsules, sugar or film coated
25 tablets, liquid solutions or suspensions; rectally, in

the form of suppositories; parenterally, e.g. intramuscularly or by intravenous injection or infusion.

The dosage level suitable for administration to adult humans depends on the age, weight, conditions of the patient and on the administration route; for example, the
5 dosage adopted for oral administration for the compounds of the invention may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily.

The present invention also provides pharmaceutical
10 compositions comprising a compound of the invention as an active ingredient in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).

Furthermore, the present invention provides
15 pharmaceutical compositions comprising a compound of the invention, as an active ingredient, in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent) for use as kynurenine 3-hydroxylase inhibitor.

20 The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain,
25 together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches,
30 arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid,

alginates or sodium starch glycolate; effervescent mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used
5 in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersions for oral administration may be
10 e.g. syrups, emulsions and suspensions.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as
15 carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethyl-cellulose, or polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain, together with the active
20 compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as carrier, for
25 example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene
30 sorbitan fatty acid ester surfactant or lecithin.

The following examples illustrate but do not limit the invention:

Example 1

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid. (FCE 29256)

5

To 1,2-dichlorobenzene (60 ml ; 0.53 mol), (R,S)-N-trifluoroacetylaspatic anhydride (20 g ; 0.09 mol) was added in one portion, under dry nitrogen atmosphere at room temperature. To the resulting well stirred suspension, anhydrous aluminium trichloride (36 g.; 0.27 mol) was slowly added portionwise, under dry nitrogen atmosphere, maintaining the temperature below 10°C. The so obtained deep-red solution was stirred at 60°C for 4 hrs, then cooled at room temperature.

15 To the resulting reaction mixture, 6N aqueous hydrochloric acid was slowly dropped in, maintaining the temperature below 30°C on cooling. The so obtained yellow suspension was poured into ice/water (200g / 200ml), and hexane (200 ml) was added. The resulting suspension was stirred 30 min., then filtered to provide the crude reaction product as slightly yellow solid, which was washed with water and then with hexane, the resulting solid was then dried in a vacuum oven at 50°C.

25 Recrystallisation from hexane/ethyl ether afforded the pure titled compound as colourless prisms (22 g; 68%), m.p. 172-173°C.

¹H-NMR (200 MHz ; d₆-DMSO) ppm : 3.60 (d , 2H); 4.78 (d , 1H); 7.79 (d , 1H); 7.90 (dd , 1H); 8.18 (d , 1H); 9.70 (d , 1H), 13.20 (broad s, 1H).

30 MS (EI ; m/z): 357 (M⁺ ; 2.5), 304 (12), 173 (100)

Microanalysis:

calcd. for $C_{12}H_8Cl_2F_3NO_4$: C 40.26 ; H 2.23 ; N 3.91 ; Cl 19.83.

5 found : 39.53 ; 2.41 ; 3.79 ; Cl 20.17.

Analogously starting from (R,S)-N-trifluoroacetylaspartic anhydride the following compounds were obtained:

10 (R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-difluorophenyl)butanoic acid, (FCE 29434), m.p. 159-160°C.

1H -NMR (200 MHz ; d_6 -DMSO) ppm : 3.58 (d , 2H); 4.78 (m , 1H); 7.60-8.10 (m, 3H); 9.70 (d , 1H),
15 13.20 (broad s, 1H)

MS (EI; m/z): 325 (M^{+} ; 4.5), 307 (55.3), 210 (50), 141 (100)

Microanalysis: calcd. for $C_{12}H_8F_5NO_4$: C 44.35 ; H 2.45 ; N 4.35.

20 found: 44.52 ; 2.61 ; 4.08

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chloro-4'-methoxyphenyl)butanoic acid, (FCE 29573), m.p. 164-65°C.

25 1H -NMR (200 MHz ; d_6 -DMSO) ppm : 3.58 (m , 2H); 3.96 (s , 3H); 4.78 (m , 1H); 7.30 (d , 1H); 7.98 (d,1H); 8.0 (s , 1H); 9.70 (d , 1H); 13.10 (broad s , 1H)

MS (EI ; m/z): 353.1 (M^{+} ; 5), 169.0 (100)

30 Microanalysis: calcd. for $C_{13}H_{11}ClF_3NO_5$: C 44.16 ; H 3.13 ; N 3.96 ; Cl 10.04.

found: 44.15 ; 3.22 ; 3.92 ; 9.41.

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluoro-4'-methoxyphenyl)butanoic acid, (FCE 29574), m.p. 177-78°C.

5 $^1\text{H-NMR}$ (200 MHz ; $\text{d}_6\text{-DMSO}$) ppm : 3.53 (m , 2H); 3.92 (s , 3H); 4.78 (m , 1H); 7.30 (t , 1H); 7.72-7.83 (m , 2H); 9.68 (d , 1H); 13.10 (s , 1H)

MS (EI; m/z): 319.0 (8), 153.0 (100)

Microanalysis: calcd. for $\text{C}_{13}\text{H}_{11}\text{F}_4\text{NO}_5$: C 46.29 ; H 3.29 ; N 4.15.

found: 46.52 ; 3.44 ; 4.08.

Example 2

(S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (FCE 29435)

To 1,2-dichlorobenzene (60 ml ; 0.53 mol), (S)-N-trifluoroacetylaspatic anhydride (20 g ; 0.09 mol) was added in one portion, under dry nitrogen atmosphere at room temperature. To the resulting well stirred suspension, anhydrous aluminium trichloride (36 g. ; 0.27 mol) was slowly added portionwise, under dry nitrogen atmosphere, maintaining the temperature below 10°C. The so obtained deep-red solution was stirred at 25 50°C for 6 hrs, then cooled at room temperature.

To the resulting reaction mixture, 6N aqueous hydrochloric acid was slowly dropped in, maintaining the temperature below 30°C on cooling. The so obtained yellow suspension was poured into ice/water (200g / 200ml), and 30 hexane (200 ml) was added. The resulting suspension was stirred 30 min., then filtered to provide the crude reaction product as slightly yellow solid, which is

washed with water and then with hexane, the resulting solid was then dried in a vacuum oven at 50°C.

Recrystallisation from hexane/ethyl ether afforded the pure titled compound as colourless prisms (20 g;
5 56%), m.p. 154° C.

$$[\alpha]_D = + 16.27^\circ \text{ (c= 1; abs EtOH)}$$

¹H-NMR (200 MHz ; d₆-DMSO) ppm : 3.60 (d , 2H);
10 4.78 (d , 1H); 7.79 (d , 1H); 7.90 (dd , 1H); 8.18 (d , 1H); 9.70 (d , 1H), 13.20 (broad s, 1H).

MS (EI ; m/z): 357 (M⁺ ; 2.5), 304 (12), 173 (100)

Microanalysis: calcd. for C₁₂H₈ Cl₂F₃NO₄ : C 40.26
15 ; H 2.23 ; N 3.91 ; Cl 19.83.
found: 40.66 ; 2.38 ; 3.72 ; Cl 19.68.

Analogously (R)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid was obtained starting
20 from (R)-N-trifluoacetylaspatic anhydride.

m.p. 154°C

$$[\alpha]_D = - 15.1^\circ \text{ (c= 1; abs. EtOH)}$$

Microanalysis: calcd. for C₁₂H₈ Cl₂F₃NO₄ : C 40.26
; H 2.23 ; N 3.91 ; Cl 19.83.
25 found: 40.38 ; 2.80 ; 3.22 ; Cl 18.91.

Analogously starting from the corresponding homochiral N-trifluoacetylaspatic anhydride the following compounds were obtained:

30 (S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-difluorophenyl)butanoic acid (FCE 29571); colourless prisms, m.p. 136-137°C.

25

$[\alpha]_D = + 9.79^\circ$ ($c = 0.9$; 95% EtOH)

$^1\text{H-NMR}$ (200 MHz ; $d_6\text{DMSO}$, ppm): 3.58 (d , 2H); 4.78 (m , 1H); 7.60-8.10 (m, 3H); 9.70 (d , 1H), 13.10 (broad s, 1H)

5 MS (EI) : 325 (M^+), 141.0 (100)

Microanalysis: calcd. for $\text{C}_{12}\text{H}_8\text{F}_5\text{NO}_4$: C 44.35 ; H 2.45 ; N 4.35.

found : 44.20 ; 2.43 ; 4.34

10

(R)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-difluorophenyl)butanoic acid, (FCE 29572), m.p. 136-137°C.

$[\alpha]_D = - 11.4^\circ$ ($c = 0.7$; 95% EtOH)

15 Microanalysis: calcd. for $\text{C}_{12}\text{H}_8\text{F}_5\text{NO}_4$: C 44.35 ; H 2.45 ; N 4.35.

found: 44.43 ; 2.55 ; 4.29

Example 3

20 (R,S)-N-benzyloxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (FCE 29436)

To an ice cooled suspension of (R,S)-2-amino-4-oxo-4-(3',4'-dichlorophenyl) butanoic acid hydrochloride (10 g , 33.5 mmol), in water (70 ml) , 1N sodium hydroxyde (70 ml , 70 mmol) was dropped in under vigorous stirring. To the resulting solution benzylchloroformate (6.5 ml , 43.5 mmol) and 2N aqueous sodium hydroxyde (23 ml , 46 mmol) were slowly added, from two different dropping funnels, maintaining the reaction temperature below 5°C. The resulting reaction mixture was then stirred at room

25
30

temperature for two hours, during this time a colourless solid slowly precipitated.

Then the reaction mixture was cooled at 0°C, and on stirring, 2N aqueous hydrochloric acid was slowly added
5 until the pH of the reaction mixture was 2.

The resulting colourless solid was filtered, washed with water and then with hexane, and dried in a vacuum-oven at 60°C.

Recrystallisation of this crude material from ethyl
10 eter/ hexane afforded the pure titled compound as colourless prisms (9.5 g , 72 %yield), melting at 141-142°C.

¹H-NMR (200 MHz ; d₆-DMSO) ppm : 3.43 (d , 1H);
15 4.50 (q , 1H); 5.0 (s , 2H); 7.30 (s , 5H); 7.58 (d , 1H); 7.67-7.90 (m , 2H); 8.10 (s , 1H); 12.80 (broad s , 1H)

MS (FAB⁺; m/z): 396.2 (30); 352.2 (18); 217.4 (100).

20 Microanalysis: calcd. for C₁₈H₁₅Cl₂NO₅ : C 54.56 ;
H 3.82 ; N 3.54 ; Cl 17.89 .
found: 54.68; 3.83 ; 3.52 ; 17.97 .

Using the same procedure the following compounds
25 were obtained:

(R,S)-N-methoxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (FCE 29593), m.p. 178-180°C.

30 ¹H-NMR (200 MHz ; d₆-DMSO) ppm : 3.42 (d , 2H);
3.56 (s , 3H); 4.50 (q , 1H); 7.43 (d , 1H); 7.80 (d ,

1H); 7.92 (dd , 1H), 8.18 (d , 1H); 12.80 (broad s , 1H)

MS (EI ; m/z): 319.0 (2); 301.0 (8); 200 (16); 173.0 (100).

5 Microanalysis: calcd. for $C_{12}H_{10}Cl_2NO_5$: C 45.02 ; H 3.46 ; N 4.38 ; Cl 22.15 .

found: 45.06; 3.58 ; 4.29 ; 21.95 .

(R,S)-N-acetyl-2-amino-4-oxo-4-(3',4'-dichloro
10 phenyl)butanoic acid (FCE 29585), Was obtained with the above reported procedure using Na_2CO_3 - $NaHCO_3$ buffer instead of NaOH; m.p. 199-203°C (a first solid-liquid transition was detected by DSC at 190-194°C).

15 1H -NMR (200 MHz ; d_6 -DMSO) ppm : 1.80 (s , 3H); 3.42 (d , 2H); 4.65 (q , 1H); 7.79 (d , 1H); 7.90 (d , 1H); 8.13 (s , 1H); 8.16 (d , 1H); 12.65 (broad s , 1H)

Microanalysis: calcd. for $C_{12}H_{10}Cl_2NO_4$: C 47.39; H 3.65 ; N 4.61 ; Cl 23.32 .

20 found: 47.38; 3.68 ; 4.54 ; 23.21.

(R,S)-N-benzoyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (FCE 29584), m.p. 175°C dec.

25 1H -NMR (200 MHz ; d_6 -DMSO) ppm : 3.52 (d , 2H); 4.85 (q , 1H); 7.30-7.58 (m , 3H); 7.78-7.82 (m , 3H); 7.90-7.96 (m , 1H); 8.18 (s , 1H); 8.60 (d , 1H).

Microanalysis: calcd. for $C_{17}H_{14}Cl_2NO_4$: C 55.76 ; H 3.58 ; N 3.82 ; Cl 19.36 .

30 found: 53.71; 3.53 ; 3.70 ; 20.57.

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chlorophenyl)-butanoic acid; and

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluorophenyl)-butanoic acid.

5

Example 4

(R,S)-N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (FCE 29581)

10 To a solution of (R,S)-methyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoate hydrochloride (1.0 g , 3.2 mmol) in dry chloroform (50 ml), cooled at -10°C and under dry nitrogen atmosphere, triethylamine (0.9 ml , 6.4 mmol) dissolved in dry chloroform (10 ml) was slowly dropped
15 in, keeping the temperature below 0°C. To the stirred resulting suspension, a solution of mesylchloride (0.36 ml, 3.3 mmol) in dry chloroform (10 ml) was added during 15 min., on cooling at 0°C. The resulting yellow reaction mixture was stirred at room temperature further 30 min.,
20 and then washed with ice cooled saturated sodium bicarbonate solution, 0.5 N hydrochloric acid solution and then with brine, dried (Na₂SO₄) and evaporated under reduced pressure.

The resulting crude material was recrystallised from
25 ethyl ether/hexane to yield (R,S)-methyl-N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoate as colourless needles (g 0.98 , 89 %), melting at 126-127°C.

¹H-NMR (200 MHz ; d₆-DMSO) ppm : 2.98 (s , 3H);
30 3.52 (d , 2H); 3.66 (s , 3H); 4.48 (q , 1H); 7.70
(d , 1H); 7.80 (d , 1H); 7.92 (dd , 1H); 8.15
(d, 1H).

To a solution of the above (R,S)-methyl-N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoate (300 mg , 0.84 mmol) in 95% ethanol (20 ml), cooled at 0°C, 1N aqueous sodium hydroxyde solution (1.7 ml , 1.7 mmol) was added.

The resulting reaction mixture was stirred at 0°C for 3 hours, then neutralised with glacial acetic acid, the most of ethanol was evaporated under reduced pressure, and the residue taken up with ethyl acetate (50 ml), washed with 0.5 N hydrochloric acid and then with brine, dried (Na₂SO₄), and evaporated under reduced pressure.

The resulting light yellow solid was recrystallised twice from ethyl ether to provide the pure titled acid as colourless needles (184 mg , 65%), melting at 219°C.

¹H-NMR (200 MHz ; d₆-DMSO) ppm : 2.96 (s , 3H); 3.45 (d , 2H); 4.38 (q , 1H); 7.56 (d , 1H); 7.80-7.95 (m , 2H); 8.08 (s , 1H); 12.95 (broad s , 1H)

MS (FAB⁺ ; m/z): 338.3 (80; M+H⁺); 243.0 (100)

Microanalysis:

calcd. for C₁₁H₁₁Cl₂NO₅ S: C 38.86 ; H 3.26 ; N 4.12 ; S 9.41 ; Cl 20.88 .
found: 39.51; 3.53 ; 4.14 ; 9.33 ; 20.85 .

Example 5

(R,S)-methyl-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoate.

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid (1.0 g , 2.8 mmol) dissolved in dry methanol (30 ml) was treated at room temperature with 6N methanolic solution of hydrochloric acid (0.9 ml). The resulting solution was warmed on

stirring at 40°C for 4 hrs. , then the solvent was distilled off in vacuum, and the residue was taken up with ethyl ether (100 ml); the organic phase was washed with aqueous sodium bicarbonate, then with brine, dried
5 (Na_2SO_4), and evaporated under reduced pressure.

The resulting oily material was crystallised with hexane/ isopropyl ether to provide the pure titled compound as colourless solid (0.98 g ; 96 %), melting at 97-98°C.

10

^1H -NMR (200 MHz ; CDCl_3) ppm : 3.55 (dd , 1H); 3.81 (s , 3H); 3.87 (dd , 1H); 4.96 (m , 1H); 7.43 (d , 1H); 7.58 (d , 1H); 7.75 (dd , 1H); 8.0 (d , 1H).

MS (EI; m/z): 371 (4); 339 (18); 173 (100).

15

Microanalysis: calcd. for $\text{C}_{13}\text{H}_{10}\text{Cl}_2\text{F}_3\text{NO}_4$: C 41.96 ; H 2.71 ; N 3.76 ; Cl 19.05 .

found: 41.83; 2.76 ; 3.56 ; 21.03 .

Example 6

20

Capsules, each weighing 0.23 g and containing 50 mg of the active substance can be prepared as follows:

Composition for 500 capsules:

25

(R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid	25 g
Lactose	80 g
Corn starch	5 g
Magnesium stearate	5 g

30

This formulation can be encapsulated in two hard gelatin capsules of two pieces, each with each capsule weighing 0.23 g.

Example 7Intramuscular injection of 50 mg/ml

A pharmaceutical injectable composition can be manufactured dissolving 50 g of

- 5 (R,S)-N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid in sterile propyleneglycol (1000 ml) and sealed in 1-5 ml ampoules.


Legend to Figure 1, which shows kynurenine pathway

- 10 IDO : Indolamineoxygenase
TDO : Tryptophanedioxygenase
KYN : Kynurenine
KYN-3-OHase : Kynurenine-3-hydroxylase
KYN-3-OH : 3-Hydroxy kynurenine
15 KAT : Kynurenine amino transferase
3-OHAA : 3-Hydroxy anthranilic acid
KYNase : Kynureninase
3-HAO : 3-Hydroxy anthranilic acid dioxygenase
KYNA : Kynurenic acid
20 QUIN : Quinolinic acid

CLAIMS

1. A N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of formula (I)

5



wherein

10 each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SOR₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen,
15 C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or benzyl;

R is hydroxy; -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in which each of R₃ is as defined above;

20 W is -COOR₄, -COR₄ or -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl; -CONHR₅ or -CSNHR₅ in which R₅ is as defined above; trichloroacetyl; or trifluoroacetyl;

25 or a pharmaceutically acceptable salt thereof, for use as a medicament.

2. A compound as defined in claim 1 for use as Kynurenine 3-hydroxylase inhibitor.

3. A compound of formula (I), according to claim 1, wherein

each of the groups X and Y is, independently,
5 hydrogen; halogen; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SOR₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; SO₂N(R₃)₂ in which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, optionally substituted phenyl or benzyl;
10 R is hydroxy;

W is -COOR₄, -COR₄ or -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl, trichloroacetyl or trifluoroacetyl;

15 and the pharmaceutically acceptable salts thereof.

4. A compound of formula (I) according to claim 1, which is selected from the group consisting of:

N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)

20 butanoic acid;

N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chlorophenyl)-
butanoic acid;

N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluorophenyl)-
butanoic acid;

25 N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-
butanoic acid;


N-trifluoroacetyl-2-amino-4-oxo-4-(3',4'-difluorophenyl)-
butanoic acid;

30 N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chloro-4'-
methoxyphenyl)-butanoic acid;

N-acetyl-2-amino-4-oxo-4-(3',4'-dichloro phenyl)butanoic
acid;

- N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluoro-4'-methoxyphenyl)-butanoic acid;
- N-benzoyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
- 5 N-methoxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
- N-benzyloxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid; either as single enantiomers or as mixture of enantiomers or a
- 10 pharmaceutically acceptable salt thereof.
5. A compound selected from:
- N-methylsulfonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)butanoic acid;
- 15 N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chlorophenyl)-butanoic acid;
- N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluorophenyl)-butanoic acid;
- N-trifluoroacetyl-2-amino-4-oxo-4-(3'-chloro-4'-methoxyphenyl)-butanoic acid;
- 20 N-trifluoroacetyl-2-amino-4-oxo-4-(3'-fluoro-4'-methoxyphenyl)-butanoic acid;
- N-benzoyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid;
- 25 N-methoxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid; and
- N-benzyloxycarbonyl-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid
- either as single enantiomers or as mixture of enantiomers
- 30 or a pharmaceutically acceptable salt thereof.

6. A compound of formula (Ia)



5 wherein

each of the groups X and Y is, independently, hydrogen; halogen; nitro; C₁-C₆ alkyl; C₂-C₄ alkenyl; C₂-C₄ alkynyl; C₁-C₆ alkoxy; C₁-C₆ alkylthio; SO₂R₂ or SO₂R₂ in which R₂ is C₁-C₆ alkyl, phenyl or benzyl; or SO₂N(R₃)₂ in
 10 which each of the groups R₃ is, independently, hydrogen, C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, phenyl or benzyl;

R is hydroxy; -OR₅ in which R₅ is C₁-C₆ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl or benzyl; -N(R₃)₂ or -N(R₃)OR₃ in
 15 which each of R₃ is as defined above;

W is -SO₂R₄ in which R₄ is C₁-C₆ alkyl, an optionally substituted C₂-C₄ alkenyl, an optionally substituted phenyl or benzyl; -CONHR₅ or -CSNHR₅ in which R₅ is as defined above; or a pharmaceutically acceptable salt
 20 thereof.

7. A compound of formula (Ia) according to claim 6 wherein W is SO₂R₄ in which R₄ is C₁-C₄ alkyl and X and Y, which may be the same or different are hydrogen or
 25 halogen, or a pharmaceutically acceptable salt thereof.


8. A compound of formula (Ia) according to claim 6 which is N-methylsulphonyl-2-amino-4-oxo-4-(3', 4'-dichlorophenyl)butanoic acid, either as single enantiomer

or as a mixture thereof, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition which comprises, as an active principle, a compound of formula (I) or (Ia), as defined in claim 1 or 6, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier and/or diluent.
10. Use of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for use as kynurenine-3-hydroxylase inhibitor.
11. A method of inhibiting kynurenine-3-hydroxylase enzyme in a mammal, including humans, in need of such inhibition, comprising administering thereto a kynurenine-3-hydroxylase enzyme-inhibiting effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.

1/1

Figure 1



INTERNATIONAL SEARCH REPORT

Interr. al Application No
PCT/EP 97/04271

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C229/36 C07C271/14 C07C271/12 C07C311/06 A61K31/195
A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 97 15550 A (PHARMACIA & UPJOHN S.P.A.) 1 May 1997 see claim 3 formula IV	1
A,P	see claim 3 ---	9,10
X	WO 95 03271 A (PHARMACIA S.P.A.) 2 February 1995 cited in the application see claims 3,10,11; examples 2,7,12,13 ---	1,9,10
A	WO 95 04714 A (UNIVERSITY OF MARYLAND AT BALTIMORE ET AL) 16 February 1995 -----	1,9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

24 November 1997

Date of mailing of the international search report

08.12.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kapteyn, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/04271

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9715550 A	01-05-97	AU 7285296 A	15-05-97
WO 9503271 A	02-02-95	IT 1265101 B	30-10-96
		AU 678273 B	22-05-97
		AU 7228594 A	20-02-95
		CN 1112786 A	29-11-95
		EP 0662948 A	19-07-95
		FI 951298 A	20-03-95
		HU 70478 A	30-10-95
		JP 8501805 T	27-02-96
		NO 951100 A	22-03-95
		NZ 268896 A	29-01-97
		PL 308142 A	24-07-95
		ZA 9405425 A	01-03-95
WO 9504714 A	16-02-95	US 5519055 A	21-05-96
		AU 680672 B	07-08-97
		AU 7360294 A	28-02-95
		CA 2145178 A	16-02-95
		CN 1113386 A	13-12-95
		EP 0663899 A	26-07-95
		FI 951631 A	05-04-95
		HU 70394 A	30-10-95
		JP 8502523 T	19-03-96
		PL 308237 A	24-07-95
		ZA 9405830 A	09-03-95